EHA 2020 | ZELLA 101: alvocidib for newly diagnosed AML

Name: ZELLA 101: alvocidib for newly diagnosed AML
Uploaded: 2020-06-08T00:00:00Z
Duration: 6 min 20 s
Description: Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses results from the Phase I ZELLA 101 study of alvocidib, a CDK9 kinase inhibitor, for newly diagnosed acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Joshua Zeidner • 8 Jun 2020

EHA 2020

Acute Myeloid Leukemia Leukemia Alvocidib Cytarabine Daunorubicin Mitoxantrone

ZELLA 101

Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses results from the Phase I ZELLA 101 study of alvocidib, a CDK9 kinase inhibitor, for newly diagnosed acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).